{"product_id":"phg-vrio-analysis","title":"Koninklijke Philips N.V. (PHG): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to Koninklijke Philips N.V. (PHG)'s enduring success starts here: this VRIO analysis distills exactly where its competitive advantage lies, based on the findings in \u0026amp;O4\u0026amp;. Are its core assets truly Valuable, Rare, Inimitable, and Organized for sustained dominance? Click through below to see the sharp, one-paragraph summary and find out if Koninklijke Philips N.V. (PHG) is built to last.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eKoninklijke Philips N.V. (PHG) - VRIO Analysis: \u003cstrong\u003e1. AI-Driven Health Informatics \u0026amp; Imaging Platform\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eYou're looking at how Koninklijke Philips N.V.'s deep dive into AI for imaging and informatics translates into a real competitive moat. Honestly, the speed at which they are rolling out FDA-cleared tools like SmartSpeed Precise suggests they are building something tough to copy.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Workflow Optimization and Diagnostic Edge\u003c\/h3\u003e\n\u003cp\u003eThis platform definitely delivers tangible value by directly tackling the crunch in radiology departments. The SmartSpeed Precise dual AI reconstruction software, which got its FDA 510(k) clearance in July 2025, is a prime example. It lets clinicians run MRI scans up to \u003cstrong\u003e3x faster\u003c\/strong\u003e while producing images that are up to \u003cstrong\u003e80% sharper\u003c\/strong\u003e compared to older SENSE imaging.\u003c\/p\u003e\n\u003cp\u003eThis isn't just about speed; it’s about access and accuracy. Think about the math: if you cut scan time by two-thirds, you can immediately boost patient throughput, helping address those growing wait times you see mentioned in the Future Health Index 2025 Global Report. Also, the MR Workspace R12 software automates \u003cstrong\u003e80%\u003c\/strong\u003e of MRI procedures with its SmartExam feature.\u003c\/p\u003e\n\u003cp\u003eHere are the key value drivers:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eScans up to \u003cstrong\u003e3x faster\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eImages up to \u003cstrong\u003e80% sharper\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAutomates \u003cstrong\u003e80%\u003c\/strong\u003e of MRI procedures.\u003c\/li\u003e\n\u003cli\u003eDiagnosis \u0026amp; Treatment segment saw \u003cstrong\u003e+1.3%\u003c\/strong\u003e comparable sales growth in Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity: Deep, Integrated Dual-AI Deployment\u003c\/h3\u003e\n\u003cp\u003eWhat makes this rare is the depth of integration across the installed base, not just in new machines. SmartSpeed Precise is cleared for use across Philips' entire portfolio of \u003cstrong\u003e1.5T and 3.0T MRI systems\u003c\/strong\u003e. That broad compatibility means a massive, immediate impact that few rivals can match with a single, unified software upgrade.\u003c\/p\u003e\n\u003cp\u003eIt’s not just one AI trick; it’s a dual AI solution combining Adaptive CS-NET for denoising and Precise Image Net for sharpening. That level of proprietary, clinically-validated, dual-layer AI reconstruction is scarce in the market right now.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Data Moat and Talent Investment\u003c\/h3\u003e\n\u003cp\u003eImitating this platform is tough because it requires more than just coding; it needs years of proprietary clinical data to train those deep learning models. You can’t just buy that overnight. Philips is backing this up with serious capital; they maintain an annual \u003cstrong\u003e$900 million\u003c\/strong\u003e R\u0026amp;D investment in the US alone, and recently announced an additional \u003cstrong\u003e$150 million\u003c\/strong\u003e investment specifically for US-based AI health tech manufacturing and R\u0026amp;D.\u003c\/p\u003e\n\u003cp\u003eWhat this estimate hides is the cost of acquiring the specialized clinical R\u0026amp;D talent needed to maintain this pace. It’s a long-term commitment that acts as a significant barrier to entry for smaller players.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Clear Strategic Focus\u003c\/h3\u003e\n\u003cp\u003eThe organizational structure seems aligned to push this advantage. The fact that they are funneling significant new investment - over \u003cstrong\u003e$150 million\u003c\/strong\u003e - into expanding US manufacturing for AI-enabled systems shows clear commitment. Plus, the Q3 2025 results show the Diagnosis \u0026amp; Treatment segment, where this platform lives, is stabilizing with \u003cstrong\u003e+1.3%\u003c\/strong\u003e comparable sales growth, suggesting the innovations are starting to stick with customers.\u003c\/p\u003e\n\u003cp\u003eThe company is organized to capitalize on these software upgrades, as seen by the focus on expanding manufacturing capacity for these AI-enabled ultrasound systems in places like Reedsville, PA, adding \u003cstrong\u003e24,000\u003c\/strong\u003e square feet of manufacturing space.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage Summary\u003c\/h3\u003e\n\u003cp\u003eThe combination of a high-value, rare, and difficult-to-replicate technology, supported by strong organizational commitment and investment, points toward a durable lead.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on the VRIO assessment:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eKey Supporting Data (2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e3x\u003c\/strong\u003e faster scans; \u003cstrong\u003e80%\u003c\/strong\u003e sharper images.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eDual AI integration across installed \u003cstrong\u003e1.5T\/3.0T\u003c\/strong\u003e MRI base.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability (I)\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eRequires massive proprietary data sets; backed by \u003cstrong\u003e$900M+\u003c\/strong\u003e annual US R\u0026amp;D.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eStrong\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$150M+\u003c\/strong\u003e new investment in US AI manufacturing\/R\u0026amp;D; segment sales stabilizing.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eContinuous innovation cycle creates a moving target for rivals.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eIf onboarding takes 14+ days longer than expected for these new software features, churn risk rises for the installed base. Finance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eKoninklijke Philips N.V. (PHG) - VRIO Analysis: \u003cstrong\u003e2. Scale of Intellectual Property (IP) Portfolio\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Protects core technology across hardware, software, and services, generating licensing income and blocking competitors in key medical device areas.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many large firms have IP, but Philips’ specific scale in MedTech is notable.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. Competitors can't easily replicate the 50,500 patent rights and 150,000 design rights amassed over a century.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Effective. They are consistently recognized as the top-ranked medical technology company in the Clarivate Top 100 Global Innovators 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. The sheer volume and quality of patents act as a significant barrier to entry and imitation.\u003c\/p\u003e\n\u003cp\u003eThe scale of the portfolio is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP Asset\u003c\/td\u003e\n\u003ctd\u003eCount (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent Rights\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50,500\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDesign Rights\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e150,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrademarks\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30,500\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomain Names\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3,200\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eR\u0026amp;D investment metrics supporting the IP scale:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D Investment (2024): Approximately \u003cstrong\u003eEUR 1.7 billion\u003c\/strong\u003e, representing \u003cstrong\u003e\u0026gt;9%\u003c\/strong\u003e of sales.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D Expenses (2024): \u003cstrong\u003e$1.89B\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNew Patents Filed (2024): \u003cstrong\u003e700\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDutch R\u0026amp;D Investment (2024): \u003cstrong\u003e€650 million\u003c\/strong\u003e, ranking 2nd in the Netherlands R\u0026amp;D Top 50.\u003c\/li\u003e\n\u003cli\u003eLives Improved by Innovations (2024): Nearly \u003cstrong\u003e2 billion\u003c\/strong\u003e people.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eKoninklijke Philips N.V. (PHG) - VRIO Analysis: \u003cstrong\u003e3. Enterprise-Wide Productivity \u0026amp; Cost Discipline\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Directly drives margin expansion, offsetting macro headwinds like tariffs, and improves cash flow resilience. The 12.3% Adjusted EBITA margin in Q3 2025 was achieved while navigating estimated tariff-related costs between EUR 150 and EUR 200 million for 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate. Many companies aim for this, but execution at this scale is less common.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Easy to moderate. The concept is easy, but replicating the specific savings structure is hard.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Very Strong. They are on track to deliver EUR 800 million in productivity savings for 2025 alone, showing disciplined execution. Productivity initiatives delivered EUR 222 million in savings in Q3 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary. While strong now, sustained cost discipline is always at risk of eroding without constant vigilance.\u003c\/p\u003e\n\u003cp\u003eProductivity and cost discipline metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Actual\u003c\/td\u003e\n\u003ctd\u003e2025 Outlook\/Target\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProductivity Savings Delivered (Quarter)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eEUR 222 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eEUR 800 million\u003c\/strong\u003e (Annual Target)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Productivity Program Target\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eEUR 2.5 billion\u003c\/strong\u003e (2023-2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITA Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e11.3%-11.8%\u003c\/strong\u003e (Full Year)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Tariff Headwind Impact (2025)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eEUR 150-200 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eEUR 172 million\u003c\/strong\u003e (Q3)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eEUR 0.2-0.4 billion\u003c\/strong\u003e (Full Year Guidance)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eProductivity initiatives have delivered EUR 2.1 billion in savings since the start of the three-year plan in 2023.\u003c\/p\u003e\n\u003cp\u003eThe productivity and pricing contribution in Q2 2025 was a substantial 3.4 percentage points to margin improvement.\u003c\/p\u003e\n\u003cp\u003eSegment performance driven by cost discipline:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eConnected Care Adjusted EBITA margin improved 410 bps to 11.4% in Q3 2025, driven by increased sales and productivity.\u003c\/li\u003e\n\u003cli\u003ePersonal Health Adjusted EBITA margin increased 60 bps to 17.1% in Q3 2025, driven by increased sales and productivity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eKoninklijke Philips N.V. (PHG) - VRIO Analysis: \u003cstrong\u003e4. Global Health Technology Brand Equity\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProvides customer trust and preference, especially in high-stakes hospital environments, supporting premium pricing and order intake momentum (\u003cstrong\u003e6%\u003c\/strong\u003e growth in Q2 2025). Group comparable sales increased \u003cstrong\u003e1%\u003c\/strong\u003e in Q2 2025, reaching sales of \u003cstrong\u003eEUR 4.3 billion\u003c\/strong\u003e for the quarter. The Adjusted EBITA margin was \u003cstrong\u003e12.4%\u003c\/strong\u003e in Q2 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate. The brand is globally recognized, though the shift from consumer electronics requires ongoing reinforcement in the health sector. The company has improved the lives of \u003cstrong\u003e1.99 billion\u003c\/strong\u003e people as of Q3 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDifficult. Brand trust, especially after recent quality focus, is built over decades and is not easily bought. The company has approximately \u003cstrong\u003e~67,000\u003c\/strong\u003e employees globally as of Q3 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEffective. The mission of improving health through meaningful innovation aligns the brand with customer needs. Free cash flow increased to \u003cstrong\u003eEUR 230 million\u003c\/strong\u003e in Q2 2025, with a leverage ratio of \u003cstrong\u003e2.2x\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained. The established trust in medical equipment is a powerful, long-term asset. The company reiterated its full-year comparable sales growth outlook at \u003cstrong\u003e1%-3%\u003c\/strong\u003e for 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePeriod\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eComparable Order Intake Growth\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup Comparable Sales Growth\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup Sales\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eEUR 4.3 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITA Margin\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree Cash Flow\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eEUR 230 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Debt\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e€6.6 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCircular Revenues\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eStrategic Partnerships and Innovation Milestones Supporting Brand Equity:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMulti-year agreement with the Indonesian Ministry of Health to expand access to cardiac, stroke, and cancer care.\u003c\/li\u003e\n\u003cli\u003eSigned long-term Enterprise Monitoring as a Service (EMaaS) partnerships with US health systems including Hoag and Rady Children's Hospital in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eLaunched Lumea IPL in the US, the world's No. 1 Intense Pulsed Light hair removal brand.\u003c\/li\u003e\n\u003cli\u003eUnveiled radiation therapy breakthroughs: Rembra RT and Areta RT CT scanners.\u003c\/li\u003e\n\u003cli\u003eNet-zero science-based target by 2045 validated by the Science Based Targets initiative (SBTi).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eKoninklijke Philips N.V. (PHG) - VRIO Analysis: \u003cstrong\u003e5. Focused Health Technology Business Segments\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe focus on distinct Health Technology business segments supports the VRIO framework through quantifiable performance metrics.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe focused structure allows for segment-specific investment leading to performance metrics such as:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDiagnosis \u0026amp; Treatment comparable sales growth in 2023: \u003cstrong\u003e11%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eConnected Care comparable sales growth in 2023: \u003cstrong\u003e5%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePersonal Health comparable sales growth in 2023: \u003cstrong\u003e3%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGroup comparable sales growth in 2023: \u003cstrong\u003e6%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSegment profitability improvements in 2023:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2023 Comparable Sales Growth\u003c\/th\u003e\n\u003cth\u003e2023 Adjusted EBITA Margin\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnosis \u0026amp; Treatment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConnected Care\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePersonal Health\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e16.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe clean separation from legacy consumer electronics is a differentiating factor compared to diversified conglomerates.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e2023 Total Sales: \u003cstrong\u003eEUR 18.2 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e2023 Diagnosis \u0026amp; Treatment Sales: EUR \u003cstrong\u003e8.8 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e2023 Connected Care Sales: EUR \u003cstrong\u003e5.1 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e2023 Personal Health Sales: EUR \u003cstrong\u003e3.6 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eAchieving this level of focus requires competitors to undertake massive structural changes, such as divestitures or spin-offs.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe operating model supports single accountability across end-to-end businesses, enabling agility.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOperating model change to end-to-end businesses announced: January 30, 2023.\u003c\/li\u003e\n\u003cli\u003eWorkforce reduction to date: approximately \u003cstrong\u003e8,000\u003c\/strong\u003e roles out of \u003cstrong\u003e10,000\u003c\/strong\u003e planned by \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal productivity savings by end of 2023: EUR \u003cstrong\u003e956 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe focused strategy facilitates faster, more relevant innovation cycles within core MedTech areas.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAI algorithms for cardiovascular ultrasound received FDA clearance in 2024.\u003c\/li\u003e\n\u003cli\u003eInstalled base of helium-free MRI scanners reached \u003cstrong\u003e1,111\u003c\/strong\u003e installations in 2024.\u003c\/li\u003e\n\u003cli\u003eGoal to improve lives by \u003cstrong\u003e2.5 billion\u003c\/strong\u003e people a year by \u003cstrong\u003e2030\u003c\/strong\u003e, including \u003cstrong\u003e400 million\u003c\/strong\u003e in underserved communities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eKoninklijke Philips N.V. (PHG) - VRIO Analysis: \u003cstrong\u003e6. Circular Economy \u0026amp; Sustainability Framework\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Meets growing customer and regulatory ESG demands while creating new revenue streams; they aim for \u003cstrong\u003e25%\u003c\/strong\u003e of sales from circular products by the end of \u003cstrong\u003e2025\u003c\/strong\u003e. Circular revenues comprised nearly \u003cstrong\u003eone-quarter\u003c\/strong\u003e of sales in \u003cstrong\u003e2024\u003c\/strong\u003e. This focus supports the broader goal of improving the lives of \u003cstrong\u003e2.5 billion\u003c\/strong\u003e people a year by \u003cstrong\u003e2030\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While many talk about it, achieving a \u003cstrong\u003e25%\u003c\/strong\u003e circular revenue target is advanced for a hardware-heavy firm. Circular revenue has grown from \u003cstrong\u003e8%\u003c\/strong\u003e in \u003cstrong\u003e2016\u003c\/strong\u003e to \u003cstrong\u003e24%\u003c\/strong\u003e in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. Requires deep re-engineering of product design, reverse logistics, and service models. This is evidenced by the need to achieve \u003cstrong\u003e100%\u003c\/strong\u003e EcoDesigned new product introductions (NPIs), which was accomplished for the first time in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Committed. This goal is embedded in their strategy and measured against their financial reality, with progress reported in the Annual Report examined by an external auditor with the same rigor as financial metrics (reasonable assurance).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. As ESG becomes standard, this advantage will normalize, but for now, it's a differentiator.\u003c\/p\u003e\n\u003cp\u003eThe commitment to circularity is supported by several measurable targets:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGenerate \u003cstrong\u003e25%\u003c\/strong\u003e of revenue from circular products, services, and solutions by \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOffer responsible take-back on \u003cstrong\u003eall\u003c\/strong\u003e professional medical equipment by \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSend \u003cstrong\u003ezero waste to landfill\u003c\/strong\u003e from sites.\u003c\/li\u003e\n\u003cli\u003eOperations are \u003cstrong\u003e100%\u003c\/strong\u003e carbon neutral since \u003cstrong\u003e2020\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAchieved \u003cstrong\u003e89%\u003c\/strong\u003e operations powered by renewable energy (Q3 \u003cstrong\u003e2025\u003c\/strong\u003e data).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe progression of circular revenue as a key performance indicator (KPI) is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear\u003c\/td\u003e\n\u003ctd\u003eCircular Revenue (% of Sales)\u003c\/td\u003e\n\u003ctd\u003eLives Improved (Billions)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e2016\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eData Not Available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e2022\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eData Not Available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e2023\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.88\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e24%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.96\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eQ3 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.99\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003e2025 Target\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eApproaching \u003cstrong\u003e2\u003c\/strong\u003e by \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eKoninklijke Philips N.V. (PHG) - VRIO Analysis: \u003cstrong\u003e7. Post-Recall Quality and Safety Governance\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Mitigates massive financial and reputational risk\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe financial impact of the governance failure and subsequent remediation is quantified by the \u003cstrong\u003eEUR 1.025 billion\u003c\/strong\u003e payment made in Q1 \u003cstrong\u003e2025\u003c\/strong\u003e for Philips Respironics recall-related medical monitoring and personal injury settlements.\u003c\/p\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe commitment to patient safety as the number one priority is evidenced by the financial magnitude of the risk mitigated:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSettlement Payment in Q1 \u003cstrong\u003e2025\u003c\/strong\u003e: \u003cstrong\u003eEUR 1.025 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTotal Devices Recalled: Over \u003cstrong\u003e15 million\u003c\/strong\u003e as of January \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTotal Estimated Recall Costs (including settlements, consent decree, remediation): Over US$\u003cstrong\u003e5 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe scale of the required overhaul following the Class I recall creates a unique, costly capability.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eFigure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecall Initiation Date\u003c\/td\u003e\n\u003ctd\u003eJune \u003cstrong\u003e2021\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA Recall Designation\u003c\/td\u003e\n\u003ctd\u003eClass I\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Deaths (MDRs related to recall, as of March 2023)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e385\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe existential driver for the rigorous, system-wide changes is unique to the firm facing the immediate consequences.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eGovernance changes are mandated organizationally, driving investments and accountability structures.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eChief Patient Safety and Quality Officer (Steve C de Baca) appointed in \u003cstrong\u003e2023\u003c\/strong\u003e, reporting to the CEO\u003c\/li\u003e\n\u003cli\u003eOversight elevated to the Executive Committee in \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eAll employees have dedicated patient safety and quality objectives in annual performance management\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eInvestments in systems and training are supported by broader operational restructuring:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMeasure\u003c\/td\u003e\n\u003ctd\u003eAmount\/Figure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProductivity Savings in Q1 \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eEUR 147 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Productivity Savings Since \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003eEUR 1.9 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Workforce Reduction Goal by \u003cstrong\u003e2025\u003c\/strong\u003e (including prior announcements)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10,000\u003c\/strong\u003e roles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eThe resulting embedded culture of quality is a non-replicable asset, demonstrated by the commitment to future goals.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGoal for Lives Improved Annually by \u003cstrong\u003e2030\u003c\/strong\u003e: \u003cstrong\u003e2.5 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e Sales: \u003cstrong\u003eEUR 18.0 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eKoninklijke Philips N.V. (PHG) - VRIO Analysis: \u003cstrong\u003e8. Reshaped Supply Chain Agility\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Ensures reliable product and service delivery, directly impacting the ability to fulfill order books and maintain customer relationships despite global tariff uncertainty.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many firms struggle here, but Philips’ explicit re-shaping effort is a specific, actionable strength.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can copy sourcing strategies, but Philips’ integrated view across hardware and software is harder to match.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Improving. This was a key focus area to ensure reliable delivery following prior pressures.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Supply chain resilience is a constant battle; it requires continuous investment to maintain.\u003c\/p\u003e\n\u003cp\u003eThe focus on supply chain reliability contributed to the following financial outcomes:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePeriod\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eComparable Sales Growth\u003c\/td\u003e\n\u003ctd\u003eFY 2023\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComparable Sales Growth\u003c\/td\u003e\n\u003ctd\u003eQ2 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITA Margin\u003c\/td\u003e\n\u003ctd\u003eFY 2023\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITA Margin\u003c\/td\u003e\n\u003ctd\u003eQ2 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComparable Order Intake Growth\u003c\/td\u003e\n\u003ctd\u003eQ1 2023\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFlat\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComparable Order Intake Growth\u003c\/td\u003e\n\u003ctd\u003eQ2 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eImprovements in execution and supply chain reliability were supported by organizational restructuring and productivity measures:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRestructuring and productivity plan savings in FY 2023: \u003cstrong\u003eEUR 956 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal productivity savings target for 2023-2025 increased to \u003cstrong\u003eEUR 2.5 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eWorkforce reduced by approximately \u003cstrong\u003e8,000\u003c\/strong\u003e roles out of \u003cstrong\u003e10,000\u003c\/strong\u003e planned by year-end 2023.\u003c\/li\u003e\n\u003cli\u003eOperating model productivity savings in Q1 2023 amounted to \u003cstrong\u003eEUR 94 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eKoninklijke Philips N.V. (PHG) - VRIO Analysis: \u003cstrong\u003e9. Global Strategic Partnership Network\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Secures long-term, large-scale revenue streams and market access, such as the nationwide agreement with Indonesia's Ministry of Health, aiming to expand access to heart, stroke, and cancer care for more than 280 million people across all 38 provinces of Indonesia. The partnership with NYU Langone Health is valued up to USD 115 million over 8 years.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: The ability to secure multi-year, national-level health system agreements is a high-level sales and relationship skill, exemplified by the award to Philips after an international, competitive bidding process against competitors like GE HealthCare, Siemens, and United Imaging for the Indonesia project.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: These partnerships rely on deep trust, proven technology, such as the advanced Azurion image-guided therapy systems deployed in Indonesia, and political\/regulatory navigation skills.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Their focus on being a preferred strategic partner across their segments supports this, with 67,800 employees generating EUR 18 billion in 2024 sales.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Once embedded in a national health system, switching costs for the customer are very high, as seen in the long-term nature of these agreements.\u003c\/p\u003e\n\u003cp\u003eThe scale and commitment of these strategic alliances are detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnership Target\u003c\/td\u003e\n\u003ctd\u003eDuration\/Term\u003c\/td\u003e\n\u003ctd\u003eValue\/Scope\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndonesia Ministry of Health\u003c\/td\u003e\n\u003ctd\u003eLong-term multiyear agreement\u003c\/td\u003e\n\u003ctd\u003eNationwide coverage for Azurion systems, benefiting over 280 million people\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNYU Langone Health\u003c\/td\u003e\n\u003ctd\u003e8-year\u003c\/td\u003e\n\u003ctd\u003eUp to USD 115 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrisma Health\u003c\/td\u003e\n\u003ctd\u003eMulti-year agreement\u003c\/td\u003e\n\u003ctd\u003eStandardize patient monitoring across a system with nearly 3,000 licensed beds\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther evidence of the network's depth includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAugusta University Health: 15-year term agreement.\u003c\/li\u003e\n\u003cli\u003eWestchester Medical Center Health Network (WMCHealth): 15-year term agreement.\u003c\/li\u003e\n\u003cli\u003eMackenzie Health: 18-year term agreement.\u003c\/li\u003e\n\u003cli\u003eMedical University of South Carolina Health (MUSC Health): 8-year deal valued at $36 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eRecent financial performance related to operational execution supporting these partnerships includes productivity savings delivered since 2023 of more than EUR 1.7 billion. For Q2 2025, Group sales were €4.3 billion.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516230623381,"sku":"phg-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/phg-vrio-analysis.png?v=1740188949","url":"https:\/\/dcf-model.com\/products\/phg-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}